International Society for Advancement of Cytometry Revenue and Competitors
Estimated Revenue & Valuation
- International Society for Advancement of Cytometry's estimated annual revenue is currently $3.7M per year.
- International Society for Advancement of Cytometry's estimated revenue per employee is $120,000
Employee Data
- International Society for Advancement of Cytometry has 31 Employees.
- International Society for Advancement of Cytometry grew their employee count by 55% last year.
International Society for Advancement of Cytometry's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Manager Member Aquisition & Retention Strategies | Reveal Email/Phone |
International Society for Advancement of Cytometry Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.4M | 7 | -22% | N/A | N/A |
#2 | $4.3M | 28 | 4% | N/A | N/A |
#3 | $1.1M | 3 | -50% | N/A | N/A |
#4 | $3.5M | 45 | -52% | $56.5M | N/A |
#5 | $0.3M | 2 | 0% | N/A | N/A |
#6 | $4.5M | 29 | 21% | N/A | N/A |
#7 | $1.9M | 10 | 0% | N/A | N/A |
#8 | $7M | 45 | 5% | N/A | N/A |
#9 | $6.7M | 37 | 6% | N/A | N/A |
#10 | $2M | 13 | -13% | N/A | N/A |
What Is International Society for Advancement of Cytometry?
ISAC’s mission is to serve a multidisciplinary community by leading technological innovation, scholarship, and the exchange of knowledge in the quantitative cell sciences. Our vision is to advance the impact of cytometry in meeting current and emerging challenges in the life, biomedical, and physical sciences. ISAC produces CYTO, the annual international congress of cell analysis technology and applications. CYTO 2019 will be held from June 22-29 in Vancouver, Canada.
keywords:N/AN/A
Total Funding
31
Number of Employees
$3.7M
Revenue (est)
55%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.3M | 31 | -6% | N/A |
#2 | $5.5M | 31 | N/A | N/A |
#3 | $3.6M | 31 | 3% | N/A |
#4 | $3.9M | 31 | 35% | N/A |
#5 | $3.6M | 31 | -6% | N/A |